米非司酮和米索前列醇联合用于头胎药物流产:文献综述

Vera Kelesidou, I. Tsakiridis, Andriana Virgiliou, T. Dagklis, A. Mamopoulos, A. Athanasiadis, I. Kalogiannidis
{"title":"米非司酮和米索前列醇联合用于头胎药物流产:文献综述","authors":"Vera Kelesidou, I. Tsakiridis, Andriana Virgiliou, T. Dagklis, A. Mamopoulos, A. Athanasiadis, I. Kalogiannidis","doi":"10.1097/ogx.0000000000001222","DOIUrl":null,"url":null,"abstract":"\n \n \n Several medications have been used to achieve medical abortion in the first trimester of pregnancy. The most commonly used is the combination of mifepristone and misoprostol; however, different doses and routes of administration have been proposed.\n \n \n \n The aim of this study was to summarize published data on the effectiveness, adverse effects, and acceptability of the various combinations of mifepristone and misoprostol in medical abortion protocols in the first trimester of pregnancy.\n \n \n \n This was a comprehensive review, synthesizing the findings of the literature on the current use of mifepristone and misoprostol for first-trimester abortion.\n \n \n \n The combination of mifepristone and misoprostol seems to be more effective than misoprostol alone. Regarding the dosages and routes, mifepristone is administered orally, and the optimal dose is 200 mg. The route of administration of misoprostol varies; the sublingual and buccal routes are more effective; however, the vaginal route (800 μg) is associated with fewer adverse effects. Finally, the acceptability rates did not differ significantly.\n \n \n \n Different schemes for first-trimester medical abortion have been described so far. Future research needs to focus on identifying the method that offers the best trade-off between efficacy and safety in first-trimester medical abortion.\n \n \n \n Obstetricians and gynecologists, family physicians\n \n \n \n After participating in this activity, the learner should be better able to discuss available combinations of mifepristone and misoprostol for first-trimester medical abortion; describe the recommended doses of misoprostol for first-trimester medical abortion; and assess the adverse effects caused by misoprostol when administered by different routes.\n","PeriodicalId":509854,"journal":{"name":"Obstetrical & Gynecological Survey","volume":"120 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combination of Mifepristone and Misoprostol for First-Trimester Medical Abortion: A Comprehensive Review of the Literature\",\"authors\":\"Vera Kelesidou, I. Tsakiridis, Andriana Virgiliou, T. Dagklis, A. Mamopoulos, A. Athanasiadis, I. Kalogiannidis\",\"doi\":\"10.1097/ogx.0000000000001222\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n \\n Several medications have been used to achieve medical abortion in the first trimester of pregnancy. The most commonly used is the combination of mifepristone and misoprostol; however, different doses and routes of administration have been proposed.\\n \\n \\n \\n The aim of this study was to summarize published data on the effectiveness, adverse effects, and acceptability of the various combinations of mifepristone and misoprostol in medical abortion protocols in the first trimester of pregnancy.\\n \\n \\n \\n This was a comprehensive review, synthesizing the findings of the literature on the current use of mifepristone and misoprostol for first-trimester abortion.\\n \\n \\n \\n The combination of mifepristone and misoprostol seems to be more effective than misoprostol alone. Regarding the dosages and routes, mifepristone is administered orally, and the optimal dose is 200 mg. The route of administration of misoprostol varies; the sublingual and buccal routes are more effective; however, the vaginal route (800 μg) is associated with fewer adverse effects. Finally, the acceptability rates did not differ significantly.\\n \\n \\n \\n Different schemes for first-trimester medical abortion have been described so far. Future research needs to focus on identifying the method that offers the best trade-off between efficacy and safety in first-trimester medical abortion.\\n \\n \\n \\n Obstetricians and gynecologists, family physicians\\n \\n \\n \\n After participating in this activity, the learner should be better able to discuss available combinations of mifepristone and misoprostol for first-trimester medical abortion; describe the recommended doses of misoprostol for first-trimester medical abortion; and assess the adverse effects caused by misoprostol when administered by different routes.\\n\",\"PeriodicalId\":509854,\"journal\":{\"name\":\"Obstetrical & Gynecological Survey\",\"volume\":\"120 8\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrical & Gynecological Survey\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/ogx.0000000000001222\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrical & Gynecological Survey","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ogx.0000000000001222","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在妊娠头三个月,有多种药物可用于药物流产。最常用的是米非司酮和米索前列醇的复方制剂,但也提出了不同的剂量和给药途径。 本研究旨在总结已发表的有关妊娠头三个月药物流产方案中米非司酮和米索前列醇不同组合的有效性、不良反应和可接受性的数据。 这是一篇全面的综述,综合了目前使用米非司酮和米索前列醇进行妊娠头三个月人工流产的文献研究结果。 米非司酮和米索前列醇联合使用似乎比单独使用米索前列醇更有效。关于剂量和给药途径,米非司酮为口服给药,最佳剂量为 200 毫克。米索前列醇的给药途径各不相同;舌下和口腔给药途径更有效,但阴道给药途径(800 微克)的不良反应较少。最后,接受率没有明显差异。 迄今为止,已介绍了不同的第一胎药物流产方案。未来的研究需要重点确定在第一胎药物流产的有效性和安全性之间进行最佳权衡的方法。 妇产科医生、家庭医生 参加本活动后,学习者应能更好地讨论米非司酮和米索前列醇用于第一胎药物流产的可用组合;描述第一胎药物流产中米索前列醇的推荐剂量;以及评估米索前列醇通过不同途径给药时引起的不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Combination of Mifepristone and Misoprostol for First-Trimester Medical Abortion: A Comprehensive Review of the Literature
Several medications have been used to achieve medical abortion in the first trimester of pregnancy. The most commonly used is the combination of mifepristone and misoprostol; however, different doses and routes of administration have been proposed. The aim of this study was to summarize published data on the effectiveness, adverse effects, and acceptability of the various combinations of mifepristone and misoprostol in medical abortion protocols in the first trimester of pregnancy. This was a comprehensive review, synthesizing the findings of the literature on the current use of mifepristone and misoprostol for first-trimester abortion. The combination of mifepristone and misoprostol seems to be more effective than misoprostol alone. Regarding the dosages and routes, mifepristone is administered orally, and the optimal dose is 200 mg. The route of administration of misoprostol varies; the sublingual and buccal routes are more effective; however, the vaginal route (800 μg) is associated with fewer adverse effects. Finally, the acceptability rates did not differ significantly. Different schemes for first-trimester medical abortion have been described so far. Future research needs to focus on identifying the method that offers the best trade-off between efficacy and safety in first-trimester medical abortion. Obstetricians and gynecologists, family physicians After participating in this activity, the learner should be better able to discuss available combinations of mifepristone and misoprostol for first-trimester medical abortion; describe the recommended doses of misoprostol for first-trimester medical abortion; and assess the adverse effects caused by misoprostol when administered by different routes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Perinatal Morbidity Among Women With a Previous Cesarean Delivery (PRISMA Trial): A Cluster-Randomized Trial Third-Trimester Fetoscopic Ablation Therapy for Types II and III Vasa Previa Impact of Adenomyosis on In Vitro Fertilization Outcomes in Women Undergoing Donor Oocyte Transfers: A Prospective Observational Study The “Freeze-All” Strategy Seems to Improve the Chances of Birth in Adenomyosis-Affected Women Gestational Weight Change in a Diverse Pregnancy Cohort and Mortality Over 50 Years: A Prospective Observational Cohort Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1